Raw materials play a critical role in cell therapy manufacturing. Choosing suboptimal materials at any stage of development ...

Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.

To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Reducing manual touchpoints is an important part of supporting more consistent and scalable manufacturing processes.

FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and gene therapies.

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - In the pharmaceutical industry, the ...

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after inking a long-term lease for manufacturing and office space in the Netherlands.

The "Cell Therapy Human Raw Materials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...